Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials

Rheumatoid Arthritis

Association between sleep disturbance and subsequent pain interference in patients with early rheumatoid arthritis

Arthritis Care Res (Hoboken)

Aydemir B, Schieir O, Valois MF, Muhammad LN, Song J, Dunlop D, Chang RW, Bartlett SJ, Bessette L, Boire G, Hazlewood G, Hitchon C, Pope J, Thorne C, Tin D, Bykerk VP, Lee YC

doi: 10.1002/acr.25568

Psoriatic Arthritis

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Arthritis Rheumatol

Kerschbaumer A, Steiner M, Khalili S, Shehab A, Jordanov A, Wildner B, Maad M, Smolen JS, Aletaha D

doi: 10.1002/art.43302

Rheumatoid Arthritis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Arthritis Rheumatol

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, Catlett IM, Maldonado MA, Wong R, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Fleischmann R

doi: 10.1002/art.70106

Rheumatoid Arthritis

Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response

Arthritis Rheumatol

Yap CF, Nair N, Morgan AW, Isaacs JD, Wilson AG, Hyrich K, Barturen G, Riva-Torrubia M, Gut M, Gut I, Alarcón Riquelme ME, Barton A, Plant D

doi: 10.1002/art.43255

Rheumatoid Arthritis

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Semin Arthritis Rheum

Dieudé P, Sparks JA, Fischer A, Chen L, Lozenski K, Dahan S, Chaballa M, Little W

doi: 10.1016/j.semarthrit.2025.152795

Rheumatoid Arthritis

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial

Lancet Rheumatol

De Marco G, Hensor EMA, Helliwell PS, Sultan S, Dubash SR, Michelena X, Coates LC, Emery P, Tan AL, McGonagle D, Marzo-Ortega H

doi: 10.1016/S2665-9913(25)00156-0

Rheumatoid Arthritis

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Arthritis Care Res (Hoboken)

Xie F, Beukelman T, McCormick NP, Curtis JR

doi: 10.1002/acr.80010

Rheumatoid Arthritis

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Ann Rheum Dis

Wientjes MHM, Atiqi S, Wolbink GJ, Nurmohamed MT, Boers M, Hooijberg F, Rispens T, de Vries A, van Vollenhoven RF, Ramiro S, van Herwaarden N, van den Bemt BJF, den Broeder AA

doi: 10.1016/j.ard.2025.03.015

Rheumatoid Arthritis

Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide study

Ann Rheum Dis

Huss V, Bower H, Björklund M, Hellgren K, Frisell T, Delcoigne B, Di Giuseppe D, Askling J, ARTIS group

doi: 10.1016/j.ard.2026.02.015

Related content

Association between sleep disturbance and subsequent pain interference in patients with early rheumatoid arthritis

Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials

Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug

Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial

Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide study